# Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

> **NCT02489968** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 880 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** empagliflozin 10 mg + linagliptin 5 mg
- **DRUG:** empagliflozin 10 mg
- **DRUG:** empagliflozin 25 mg + linagliptin 5 mg
- **DRUG:** empagliflozin 25 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02489968
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2016-11-18
- **Final completion:** 2017-06-16
- **Target enrollment:** 880 (ACTUAL)
- **Last updated:** 2018-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489968, "Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02489968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*